Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: Results of the GAUDI study (BO21000)

Blood

Volumn 122, Issue 7, 2013, Pages 1137-1143

  Radford, John ^a   Davies, Andrew ^b   Cartron, Guillaume ^c   Morschhauser, Franck ^d   Salles, Gilles ^e   Marcus, Robert ^f   Wenger, Michael ^g   Lei, Guiyuan ^h   Wassner Fritsch, Elisabeth ^g   Vitolo, Umberto ⁱ  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ LYON 1   (France)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

^h ROCHE PRODUCTS LTD   (United Kingdom)

ⁱ Azienda Ospedaliera Città della Salute e della Scienza   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; OBINUTUZUMAB; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; VIDARABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DEATH; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; INFESTATION; INFLAMMATION; INFUSION RELATED REACTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; CANCER STAGING; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; FOLLOW UP; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PROGNOSIS; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; VIDARABINE; VINCRISTINE;

EID: 84887146061     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-481341     Document Type: Article

References (31)

1. Rummel M. Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice. J Natl Compr Canc Netw. 2010; 8(SUPPL. 6):S1-S14.
2. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(4): 235-242. (Pubitemid 34438862)
3. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010; 116(12): 2040-2045.
4. Pfreundschuh M, Trümper L, Osterborg A., et al.; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7(5): 379-391.
5. Marcus R, Imrie K, Belch A., et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005; 105(4): 1417-1423. (Pubitemid 40223656)
6. Forstpointner R, Dreyling M, Repp R., et al.; German Low-Grade Lymphoma Study Group. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004; 104(10): 3064-3071. (Pubitemid 39517009)
7. Hiddemann W, Kneba M, Dreyling M., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005; 106(12): 3725-3732. (Pubitemid 41742196)
8. Herold M, Haas A, Srock S., et al.; East German Study Group Hematology and Oncology Study. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007; 25(15): 1986-1992. (Pubitemid 46972781)
9. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011; 377(9759): 42-51.
10. van Oers M.H., Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: longterm outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010; 28(17): 2853-2858.
11. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007; 99(9): 706-714. (Pubitemid 47078732)
12. Hallek M, Fischer K, Fingerle-Rowson G, et al.; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376(9747): 1164-1174.
13. Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010; 28(10): 1756-1765.
14. Mössner E., Brünker P, Moser S., et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cellmediated B-cell cytotoxicity. Blood. 2010; 115(22): 4393-4402.
15. Cartron G, Dacheux L, Salles G., Solal-Celigny P, Bardos P, Colombat P., Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002; 99(3): 754-758. (Pubitemid 34525533)
16. Honeychurch J, Alduaij W, Azizyan M., et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood. 2012; 119(15): 3523-3533.
17. Herter S, Waldhauer I, Otz T., et al. Superior efficacy of the novel type II, glycoengineered CD20 antibody GA101 vs. the type I CD20 antibodies rituximab and ofatumumab [abstract]. Blood. 2010; 116(21). Abstract 3925.
18. Salles G, Morschhauser F, Lamy T., et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012; 119(22): 5126-5132.
19. Sehn LH, Goy A, Offner F.C., et al. Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20 indolent B-cell non-Hodgkin lymphoma: preliminary analysis of the GAUSS study [abstract]. Blood. 2011; 118(21). Abstract 269.
20. Morschhauser FA, Cartron G, Thieblemont C., et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: Results from the phase II GAUGUIN study [published online ahead of print July 8, 2013]. J Clin Oncol.
21. Salles GA, Morschhauser F, Solal-Céligny P, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: Results from the phase II GAUGUIN study [published online ahead of print July 8, 2013. J Clin Oncol.
22. Cheson BD, Pfistner B, Juweid M.E., et al.; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5): 579-586. (Pubitemid 350002966)
23. Cartron C, Morschhauser F, Thieblemont C., et al. Results from a phase II study of obinutuzumab (GA101) monotherapy in relapsed/refractory chronic lymphocytic leukemia (CLL) [abstract]. Haematologica. 2011; 96(s2): 39. Abstract 0101.
24. van Oers M.H., Klasa R, Marcus R.E., et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006; 108(10): 3295-3301. (Pubitemid 44794222)
25. Tomas JF, Montalban C, Martinez-Lopez J, et al. Induction with fludarabine, cyclophosphamide and rituximab followed by maintenance with rituximab: results of a prospective study in 75 patients (LNHF-03) [abstract]. Blood. 2006; 108(11). Abstract 2762.
26. Hochster H, Weller E, Gascoyne R.D., et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009; 27(10): 1607-1614.
27. Carlile D, Meneses-Lorente G, Wassner-Fritsch E, et al. Pharmacokinetics of obinutuzumab (GA101) in patients with CD20+ relapsed/refractory malignant disease receiving concomitant chemotherapy (phase Ib study BO21000) [abstract]. Blood. 2011; 118(21). Abstract 3704.
28. Patz M, Isaeva P, Forcob N., et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol. 2011; 152(3): 295-306.
29. Klein C, Herting F, Friess T., et al. GA101, a therapeutic glycoengineered CD20 antibody recognizing a type II epitope mediates outstanding anti-tumor efficacy in non-Hodgkin's lymphoma xenograft models and superior B cell depletion [abstract]. Eur J Cancer. 2008; 6(12): 160. Abstract 504.
30. Morschhauser F, Salles G, Cartron G., et al. Dose selection for phase III studies of the monoclonal anti-CD20 antibody obinutuzumab (GA101) - a rational approach. Haematologica. 2011; 96(suppl 2): 390.
31. Rummel MJ, Niederle N, Maschmeyer G., et al.; Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381(9873): 1203-1210.